Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
Home > Patient Care > Clinical Trials: Open Enrollment   
Clinical Trials: Open Enrollment
The following is a listing of all trials currently enrolling brain tumor patients at UCLA.
 
What clinical trials are available at UCLA Neuro-Oncology?
Choosing to participate in a clinical trial is an important, personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521

Study AgentIRB IDTrial:Details
5-FC (Flucytosine)10-001147[Tg 511-09-01] A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511.:
Avastin (Bevacizumab) Genetech10-000760 (09-06-032)[AVF4535s] Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma. :
CC-22311-002219[CC-223-ST-001] :
Cediranib 10-000907[ABTC 09-03] A Phase Ib Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma. :
IMC-3G3 and IMC-1121B11-000738 (10-03-077)[ABTC 09-01] An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC- 3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Multiforme. :
PLX339711-002957[PLX108-04] A Phase II Study of Orally Administered PLX3397 in Patients with Recurrent Glioblastoma.:
RO4929097 and Bevacizumab11-000467[ABTC 10-02] Ph I/II Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma.:
Toca 51110-000484 (09-07-003)[Tg 511-08-01] A Phase 1 Ascending Dose Trial of the Safety and Toleratbility of Toca 511 in Patients with Recurrent Glioblastoma Multiforme.:
VELCADE, TMZ, RT11-002222 (09-03-084)[Velcade X05303] Ph II Trial of VELCADE (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme.:
XL765 and Temozolomide10-001735 (08-01-061)[XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Glioma. :
XL765 and Temozolomide10-001735 (08-01-061)[XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas.:
XL765 and XL14710-000344[XL765-202] An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma Who are Candidates for Surgical Resection.:



All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2012 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2012 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:2/22/2012 2:24:47 PM PST]